close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cleerly

News headline image
Cleerly's TRANSFORM Trial Sends a Mobile CT Scanner Across the South to Reach Patients in Underserved Communities
From Cleerly
Via Business Wire
News headline image
Cleerly Announces New Findings on How AI-QCT Plaque Measurements Relate to Long-Term Cardiovascular Risk
From Cleerly
Via Business Wire
News headline image
Cleerly and Allelica Partner to Launch a Polygenic Risk Score Test for Coronary Artery Disease
From Cleerly
Via Business Wire
News headline image
Cleerly to Debut Customizable Full Text Reports and Present New AI-QCT Research at SCCT2026
From Cleerly
Via Business Wire
News headline image
Cleerly to Debut Cleerly PREVIEW and Showcase New AI-QCT Research at ACC.26
From Cleerly
Via Business Wire
News headline image
Cleerly AI-QCT Demonstrates High Agreement with Invasive IVUS in INVICTUS Registry
From Cleerly
Via Business Wire
News headline image
Aetna Approves Coverage for Cleerly's AI Cardiovascular Imaging Analysis
From Cleerly
Via Business Wire
News headline image
CVCT 2025: Cleerly Late-Breaking Science Identifies Thresholds of High Plaque Burden in Non-Obstructive CAD that May Carry Greater Risk Than Obstructive Disease
From Cleerly
Via Business Wire
News headline image
Cleerly Unveils PowerScribe Integration and Lesion-Level Reporting at RSNA 2025
From Cleerly
Via Business Wire
News headline image
AHA 2025 Late-Breaking Science: Cleerly’s AI Atherosclerosis Quantification Outperforms Traditional Risk Scoring
From Cleerly
Via Business Wire
News headline image
TCT 2025 Late-Breaking Science: Quantitative Assessment of Non-Calcified Plaque Volume Drives Risk for Myocardial Infarction and Death
From Cleerly
Via Business Wire
News headline image
UnitedHealthcare and Cigna Coverage for Cleerly LABS Advanced Plaque Analysis Begins October 1st
From Cleerly
Via Business Wire
News headline image
Cigna Approves Coverage for Cleerly's AI Cardiovascular Imaging Technology
From Cleerly
Via Business Wire
News headline image
Cleerly Demonstrates Significant Cardiovascular Risk Prediction in Late-Breaking Clinical Science at European Society of Cardiology Congress 2025
From Cleerly
Via Business Wire
News headline image
Cleerly to Showcase New AI-QCT Research at SCCT2025 Annual Meeting
From Cleerly
Via Business Wire
News headline image
Cleerly Announces Key Leadership Promotions: Dr. Udo Hoffmann Named Chief Medical, Scientific and AI Officer; Amit Relia Promoted to Chief Regulatory Officer
From Cleerly
Via Business Wire
News headline image
AI Meets Value-Based Care: Cleerly and Cardiac Care Alliance Join Forces to Revolutionize Heart Disease Detection
From Cleerly
Via Business Wire
News headline image
Cleerly Unveils Groundbreaking Late-Breaking Clinical Trial Results Demonstrating AI-QCT’s Predictive Power for Women’s Cardiovascular Risk at ACC.25
From Cleerly
Via Business Wire
News headline image
Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC.25
From Cleerly
Via Business Wire
News headline image
Cleerly Brings Advanced AI Heart Imaging to the American College of Cardiology’s Chicago Community Health Fair
From Cleerly
Via Business Wire
News headline image
Bunkerhill Health and Cleerly Announce Strategic Partnership to Advance Noninvasive Cardiovascular Care
From Cleerly
Via Business Wire
News headline image
Cleerly to Present Innovative Research on Age and Sex-Specific Coronary Artery Disease at AHA Scientific Sessions 2024
From Cleerly
Via Business Wire
News headline image
Cleerly Presents Late-Breaking Research on AI-Enabled Quantitative CT Coronary Assessment for Predicting Major Adverse Cardiovascular Events at TCT 2024
From Cleerly
Via Business Wire
News headline image
Cleerly Secures CPT Category I Code for AI-QCT Advanced Plaque Analyses
From Cleerly
Via Business Wire
News headline image
Medicare Administrative Contractors Approve Coverage of Cleerly Heart Scans to Medicare Recipients
From Cleerly
Via Business Wire
News headline image
Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials
From Cleerly
Via Business Wire
News headline image
Cleerly® Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System
From Cleerly
Via Business Wire
News headline image
Cleerly® ISCHEMIA™ Software Device Billable With AMA Category I CPT® Code for Noninvasive Estimates of Fractional Flow Reserve
From Cleerly
Via Business Wire
News headline image
Cleerly® Announces CERTAIN Multicenter Clinical Trial Results
From Cleerly
Via Business Wire
News headline image
Cleerly® Launches Cleerly® ISCHEMIA™ Solution for Heart Disease Analysis
From Cleerly
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.